The Use of Immature Platelet Fraction to Assess Thrombopoiesis and Mechanisms of Treatment Effect In Immune Thrombocytopenia (ITP)

Abstract 2513 The pathogenesis of ITP involves accelerated platelet destruction and decreased platelet production. The immature platelet fraction (IPF) from the Sysmex XE2100 autoanalyzer is a marker of platelet reticulocytes, so we used it to explore the mechanisms of effect of treatments of ITP. First, 67 patients with ITP were compared to 100 healthy adult controls to test the Absolute IPF (A-IPF) as a marker of thrombopoiesis. A second study investigated the plasma glycocalicin levels, a soluble external portion of membrane glycoprotein 1bα, in conjunction with A-IPF and IPF% to assess platelet turnover and survival. The mean baseline A-IPF in both ITP study groups (2.8 ×109/L & 8.67 ×109/L ) were substantially and significantly lower than the controls (7.80 ×109/L & 10.55 ×109/L ) but the IPF% were markedly higher (28.20 ×109/L & 20.83 ×109/L vs 3.20 ×109/L & 4.55 ×109/L. In the first study, A-IPF was further validated clinically by comparing responses to a thrombopoietic agent (TPO-A) and GMA161 (an anti-FcγRIII antibody, inhibiting platelet destruction). A platelet count increment >30 ×109/L or >doubling of baseline and an A-IPF increment >10× 109/L were defined as responses. In the TPO-A sub-group, 19/34 patients had platelet and A-IPF responses; 6/34 patients had platelet responses but no A-IPF response; 8/34 had no platelet or A-IPF responses; 1/34 had an A-IPF response but no platelet response (figure). With GMA161, 2/5 patients had a platelet response without an A-IPF response; 1/5 patients had a response in both platelet count and A-IPF; 2/5 patients had no platelet or A-IPF response. Almost all increases of A-IPF >10×109 and all increases >20×109 were only seen with TPO-A (figure). These results showed, as expected, that platelet responses to a TPO-A were usually associated with increased A-IPF, whereas those with an inhibitor of FcγR-mediated destruction were usually not. The effects of IV anti-D (Winrho) and IVIG in ITP were studied. 8/8 patients treated with IV anti-D had a platelet response without any A-IPF response. 10/19 patients treated with IVIG had a platelet response without a response in A-IPF, however, 4/19 had platelet and (small) A-IPF responses (figure). These results were consistent when the same patient was studied on different episodes. In a separate study, IPF findings were compared to simultaneous samples of plasma glycocalicin levels (Beer, Blood 1994) in 21 patients. Glycocalicin Index (GCI) is a measure normalized for the platelet count. Mean plasma glycocalicin level was marginally higher in ITP patients than controls: 1.86mcg/ml (0.52–3.91) vs 1.6 mcg/ml (0.79–2.53). However, mean GCI was dramatically higher in the ITP group: 31.36 (0.368–229) vs 1.75 (0.72–2.84). For the separate treatment groups, the mean plasma glycocalicin was greatest in TPO-A treated patients and the mean GCI was greatest in IVIG & prednisolone treated patients. This illustrates the relative importance of effective platelet production and platelet turnover in these therapies. There was a statistically significant (p In summary, the results of A-IPF in ITP patients compared to healthy adult controls and in ITP patients treated with TPO-A and GMA161, demonstrate the utility of this measurement in assessing thrombopoiesis and the mechanism of treatment effect in patients with ITP. Although IVIG and IV anti-D have differing interactions with FcγR, the A-IPF results support the primary effect of anti-D and IVIG to be inhibition of platelet destruction. A small group of patients mounted both platelet and A-IPF increments to IVIG, suggesting that IVIG could also cause an increased effective platelet production. Finally, results with GCI, in a smaller number of patients, further confirmed the validity of the IPF. In the future, A-IPF could be used diagnostically (not explored in this study), for assessing response to treatment, and potentially to select the most effective treatment in individuals. Disclosures: No relevant conflicts of interest to declare.